Hans-Peter Hartung, Thomas Berger, Robert A Bermel, Bruno Brochet, William M Carroll, Trygve Holmøy, Rana Karabudak, Joep Killestein, Carlos Nos, Francesco Patti, Amy Perrin Ross, Ludo Vanopdenbosch, Timothy Vollmer, Regine Buffels, Monika Garas, Karen Kadner, Marianna Manfrini, Qing Wang, Mark S Freedman
INTRODUCTION: Ocrelizumab is an approved intravenously administered anti-CD20 antibody for multiple sclerosis (MS). The safety profile and patient preference for conventional versus shorter ocrelizumab infusions were investigated in the ENSEMBLE PLUS study. METHODS: ENSEMBLE PLUS was a randomized, double-blind substudy to the single-arm ENSEMBLE study (NCT03085810), comparing outcomes in patients with early-stage relapsing-remitting MS receiving ocrelizumab 600 mg over the approved 3...
April 22, 2024: Journal of Neurology